| 摘要: |
| 茶苯海明是一种抗组胺类药,是治疗晕动病的有效药物,具有显著的民用和军事应用价值。本文检索PubMed、the Cochrane Ear, Nose and Throat Disorders Group Trials Register、the Cochrane Central Register of Controlled Trials、EMBASE、CINAHL、Web of Science、BIOSIS Previews等数据库,归纳所有可获得的文献,综合分析茶苯海明治疗晕动病的安全性和有效性。结果显示,尽管治疗晕动病的首选药物是东莨菪碱,但茶苯海明是治疗晕动病伴发恶心和呕吐时的首选药物。这可能与茶苯海明能减少晕动刺激过程中胃的运动有关。因此在治疗伴有恶心和呕吐症状的晕动病时,应首选茶苯海明。 |
| 关键词: 茶苯海明 晕动病 抗组胺药 有效性 安全性 |
| DOI：10.16781/j.0258-879x.2016.05.0631 |
| 投稿时间：2015-11-26修订日期：2016-05-06 |
| 基金项目: |
|
| Safety and efficacy of dimenhydrinate for treatment of motion sickness |
| CHENG Ji-gao△,TANG Yi-fan△,LI Zheng-hao,LIU Peng,CAI Yi-ling* |
(Department of Nautical Special Injury, Faculty of Naval Medicine, Second Military Medical University, Shanghai 200433, China
△Co-first authors
*Corresponding author) |
| Abstract: |
| Dimenhydinate, an antihistamine agent, is effective for treating motion sickness and has a value for both civil and military application. We searched PubMed, the Cochrane Ear, Nose and Throat Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, Web of Science, BIOSIS Preview for related literatures. In this paper we reviewed the retrieved literatures and discussed the safety and efficacy of dimenhydrinate in the treatment of motion sickness. It was showed that although the first choice for motion sickness was scopolamine, dimenhydrinate was, however, the first choice for nausea and vomiting, which is partly because it can reduce gastric motility during motion sickness-inducing stimuli. Therefore, dimenhydrinate might be the first choice for treating motion sickness combined with vomiting and nausea. |
| Key words: dimenhydrinate motion sickness antihistamine efficacy safety |
